Rilastam is a novel beta-lactamase inhibitor that does not belong to the beta-lactam class and has a non-beta-lactam, diazabicyclooctane (DBO) structure. It is primarily used in combination with imipenem/cilastatin to treat infections caused by multi-drug resistant Gram-negative bacteria. The rilastam produced by Jingjing Pharmaceutical acts as a “gold medal expert” in protecting antibiotics from degradation. Many drug-resistant bacteria secrete beta-lactamases, which act like “scissors” that can break down the structure of beta-lactam antibiotics, rendering them ineffective. Unlike traditional inhibitors, rilastam’s non-beta-lactam structure makes it less susceptible to degradation by these enzymes. It can closely bind to the active sites of beta-lactamases through a reversible carbamylation reaction, preventing the enzymes from damaging the antibiotics. This binding is reversible, allowing rilastam to repeatedly exert its inhibitory effect with high efficiency. To illustrate this with an analogy: - The “body” can be compared to a home that needs protection. - “Drug-resistant bacteria” are like thieves who attempt to invade the home. - “Beta-lactam antibiotics” are the “professional security guards” designed to target the thieves’ weaknesses. - “Beta-lactamases” are like the thieves’ bodyguards, trying to prevent the security guards from entering the home and reaching the thieves. - Rilastam is like a specially hired “expert bodyguard” who does not confront the thieves directly but focuses on eliminating the bodyguards blocking the way. It uses a disguise to remain unnoticed and employs a powerful “fastener” (the sulfate group) to securely bind to the active sites of the enzymes, allowing it to repeatedly inhibit their action. Rilastam from Jingjing Pharmaceutical is the perfect choice as an enzyme inhibitor against drug-resistant bacteria, offered by a manufacturer of sterile powder formulations.